PRESS RELEASE published on 01/26/2024 at 14:00, 2 years 2 months ago Optimind Pharma - Debenture Conversion Optimind Pharma Corp. (CSE:OMND) announces agreement to convert $303,750 convertible debentures at $0.025/share, potentially issuing 23,333,500 shares. Optimind focuses on psychedelic therapies for mental health. Convertible Debentures Optimind Pharma Corp. CSE:OMND Psychedelic Therapies Mental Health
PRESS RELEASE published on 12/19/2023 at 13:30, 2 years 3 months ago Optimind Pharma Provides Corporate Update
Published on 03/26/2026 at 13:00, 1 hour 29 minutes ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 1 hour 29 minutes ago GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 1 hour 30 minutes ago Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 12:45, 1 hour 44 minutes ago Quartz Mountain Reports Strong Warrant Exercise Participation and Provides Exploration Update at Maestro Project, Central British Columbia
Published on 03/26/2026 at 14:18, 11 minutes ago RHÖN-KLINIKUM AG with consistent development in financial year 2025
Published on 03/26/2026 at 07:30, 6 hours 59 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:31, 19 hours 58 minutes ago Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 20 hours 44 minutes ago Combined General Meeting on May 05, 2026: publication of the notice of Meeting
